Travis Perkins on track despite trading conditions
Building materials supplier Travis Perkins said like-for-like sales fell in the past eleven months to the end of November, as market headwinds continue, but the outlook for the year as a whole remains unchanged.
Building materials supplier Travis Perkins said like-for-like sales fell in the past eleven months to the end of November, as market headwinds continue, but the outlook for the year as a whole remains unchanged.
The Northampton based builders merchant said like-for-like sales fell 1.8% for the 11 months to the end of November 2012 while total sales for the period increased 1.6%.
"This period included two more trading days in our merchanting and plumbing and heating divisions than for the comparable period in 2011," the group explained in a statement.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It added that its specialist merchanting division has seen a small positive impact from the closure of a competitor. Like-for-like sales at merchanting rose 1.6%.
Looking ahead Travis Perkins said: "These trends mean that our outlook for the year as a whole remains unchanged from that stated in our October interim management statement."
"We remain on target to meet consensus earnings per share and are on track to achieve our net debt target of approximately £450m at the year end."
CJ
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published
-
GSK share price surges after $2.2bn Zantac drug settlement
GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer
By Chris Newlands Published